Chemours president Gerardo Familiar buys $30,050 in stock

The president of Chemours, Gerardo Familiar Calderon, recently purchased 1,935 shares of the company's common stock on August 12, 2026, at a price of $15.53 per share, amounting to a total investment of $30,050. This occurred following a decline in the stock's value of nearly 25% over the past six months, which has since rebounded to approximately $15.26, near the acquisition price.

According to InvestingPro analysis, Chemours' stock appears slightly overvalued compared to its Fair Value estimate, placing it on the platform's watchlist of potentially overvalued stocks. After this transaction, Mr. Familiar now holds a direct beneficial ownership of 58,547.3746 shares of Chemours common stock. Experts predict the company will achieve profitability this year, with additional insights available to subscribers through 8 exclusive tips.

Further analysis is available in Chemours' Pro Research Report, among 1,400+ reports for US equities. The filing of this transaction was corrected by Eric Stein, Attorney-in-Fact, on August 13, 2026, after an administrative error in previous filings. Chemours reported mixed results for the second quarter of 2026, with earnings and revenue falling short of Wall Street expectations.

Earnings per share were $0.42 on revenue of $1.59 billion, missing analysts' forecasts of $0.50 per share and $1.66 billion in revenue. UBS downgraded Chemours' stock rating from Buy to Neutral, citing concerns over the earnings potential of Chemours' refrigerant business, TSS, due to potential destocking and market share loss by 2026.

The company's price target was also lowered from $29.00 to $18.00 by UBS analyst Joshua Spector. These factors illustrate the ongoing challenges faced by Chemours as it navigates market dynamics and investor expectations.